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Introduction: Regional citrate anticoagulation (RCA) for continuous renal replacement therapy is widely used in
intensive care units (ICUs). However, concern exists about the safety of citrate in patients with liver failure (LF). The
aim of this study was to evaluate safety and efficacy of RCA in ICU patients with varying degrees of impaired liver
function.
Methods: In a multicenter, prospective, observational study, 133 patients who were treated with RCA and
continuous venovenous hemodialysis (RCA-CVVHD) were included. Endpoints for safety were severe acidosis or
alkalosis (pH ≤7.2 or ≥7.55, respectively) and severe hypo- or hypercalcemia (ionized calcium ≤0.9 or ≥1.5 mmol/L,
respectively) of any cause. The endpoint for efficacy was filter lifetime. For analysis, patients were stratified into
three predefined liver function or LF groups according to their baseline serum bilirubin level (normal liver
function ≤2 mg/dl, mild LF >2 to ≤7 mg/dl, severe LF >7 mg/dl).
Results: We included 48 patients with normal liver function, 43 with mild LF, and 42 with severe LF. LF was
predominantly due to ischemia (39 %) or multiple organ dysfunction syndrome (27 %). The frequency of safety
endpoints in the three patient strata did not differ: severe alkalosis (normal liver function 2 %, mild LF 0 %, severe
LF 5 %; p = 0.41), severe acidosis (normal liver function 13 %, mild LF 16 %, severe LF 14 %; p = 0.95), severe
hypocalcemia (normal liver function 8 %, mild LF 14 %, severe LF 12 %; p = 0.70), and severe hypercalcemia (0 % in
all strata). Only three patients showed signs of impaired citrate metabolism. Overall filter patency was 49 % at 72 h.
After censoring for stop of the treatment due to non-clotting causes, estimated 72-h filter survival was 96 %.
Conclusions: RCA-CVVHD can be safely used in patients with LF. The technique yields excellent filter patency and
thus can be recommended as first-line anticoagulation for the majority of ICU patients.
Trial registration: ISRCTN Registry identifier: ISRCTN92716512. Date assigned: 4 December 2008.* Correspondence: torsten.slowinski@charite.de
1Department of Nephrology, University Hospital Charité, Campus Mitte
(CCM), Charitéplatz 1, D-10117 Berlin, Germany
Full list of author information is available at the end of the article
© 2015 Slowinski et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Slowinski et al. Critical Care  (2015) 19:349 Page 2 of 11Introduction
Regional citrate anticoagulation (RCA) has become a
widely used technique in continuous renal replacement
therapy (CRRT). It is suggested in actual guidelines even
in the absence of an increased bleeding risk for patients
not already receiving systemic anticoagulation and with-
out contraindications for citrate [1]. Prolonged filter pa-
tency, together with the possibility of avoiding systemic
anticoagulation, led to an increasing acceptance of the
technique [2–8]. However, regardless of the RCA proto-
col used, a considerable amount of citrate is infused into
the systemic circulation. This citrate enters the citric
acid cycle and is metabolized to bicarbonate [9]. Most
dialysis-based protocols take the bicarbonate generation
from infused citrate into account and use lower bicar-
bonate concentrations in the dialysate [6]. On one hand,
such protocols usually allow better control of the acid–
base state [10]; on the other hand, the metabolism of cit-
rate is essential to maintain sufficient delivery of bicar-
bonate. As a consequence, in such protocols, impaired
citrate metabolism translates into metabolic acidosis.
Another important issue in RCA is homeostasis of
ionized calcium (iCa). The calcium bound to citrate is
released if citrate is metabolized. In cases of impaired
citrate metabolism, iCa is not released and systemic iCa
decreases [11].
Several clinical observations raised concerns about the
efficiency of citrate metabolism in the presence of liver
failure (LF) [12]. Data showing reduced clearance of
citrate in liver dysfunction led to clinical practice of
avoiding RCA in patients with LF [11]. However, though
coagulation often is impaired in liver dysfunction [13],
filter clotting nevertheless occurs frequently [14]. There-
fore, patients with impaired liver function might particu-
larly benefit from RCA by avoidance of filter clotting
without increasing bleeding risk or interfering with
hemostasis through systemic anticoagulation.
To test the hypothesis that continuous venovenous
hemodialysis and regional citrate anticoagulation (RCA-
CVVHD) can also be recommended for patients with
LF, the safety and efficacy of RCA-CVVHD in patients
with different degrees of liver dysfunction were prospect-
ively investigated.
Material and methods
This study was a multicenter, open, prospective, observa-
tional trial (ISRCTN Registry identifier: ISRCTN92716512).
The study was performed in accordance with the
Declaration of Helsinki, and the protocol was ap-
proved by all local ethics committees. The names of
the ethical bodies that approved the study in the centers
involved are listed in the Acknowledgments section. All
consecutive patients treated with RCA-CVVHD between
January 2008 and February 2010 were considered forstudy participation. They were included if written in-
formed consent was provided by themselves or by their
legal representatives until at least 40 patients in each
group were reached. All participating centers were univer-
sity hospitals. The types of intensive care units (ICUs)
were general (Department of Nephrology, Charité CCM,
Berlin, Germany; Department of Anesthesiology, Leipzig
University Hospital, Germany), surgical (Department of
Visceral and Transplant Surgery, Charité CVK, Berlin,
Germany; Department of Anesthesiology, University
Hospital Duesseldorf, Germany; Surgical Intensive Care,
University Hospital Zurich, Switzerland; Oslo University
Hospital, Norway [OUS]), and medical (Department of
Internal Medicine I, Medical University Innsbruck,
Austria; OUS).
All patients fulfilled the following inclusion criteria:
age ≥18 years and prescription of RCA-CVVHD for
renal replacement therapy. The exclusion criteria were
former use of RCA within 72 h before the study start,
concomitant participation in another clinical trial, and
previous participation in the same study.
A total of 133 patients were included in the study. Pa-
tients were stratified into three groups according to their
liver function level, as defined by total serum bilirubin:
normal liver function with bilirubin ≤2 mg/dl, mild LF
with bilirubin >2 and ≤7 mg/dl, and severe LF with bili-
rubin >7 mg/dl.
All patients were treated with RCA-CVVHD using
the multiFiltrate device (Fresenius Medical Care, Bad
Homburg, Germany). The treatment protocol published
by Morgera et al. [6] with a calcium-free and bicarbonate-
reduced dialysate (Ci-Ca Dialysate K2 Plus; Fresenius
Medical Care) was used. The dialysate flow was initially
set as indicated by clinical needs. The blood flow was set
at three times the dialysate flow. For anticoagulation, 4 %
trisodium citrate solution was infused into the arterial line
of the extracorporeal circuit with an initial dose of
4 mmol/L blood. The citrate dose was stepwise adapted to
achieve a target postfilter iCa range of 0.25–0.35 mmol/L.
Calcium chloride solution was infused into the venous
line of the extracorporeal circuit at an initial dose of
1.7 mmol/L effluent and was adjusted to keep iCa within
the physiologic range of 1.12–1.20 mmol/L. The ratio of
dialysate flow to blood flow was increased in stepwise
fashion in cases of metabolic alkalosis and likewise de-
creased in cases of acidosis [10].
The observation period included the first 72 h of the
RCA-CVVHD treatment, which corresponded to the time
point of a regular filter exchange as specified by the
manufacturer.
Blood samples for arterial and postfilter analysis of pH,
blood gases, and electrolytes (iCa, potassium, sodium)
were taken and analyzed immediately on a bedside auto-
mated analyzer. All other laboratory parameters were
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centers (all accredited according to the International
Laboratory Accreditation Cooperation).
All measurements of arterial iCa and postfilter iCa, as
well as arterial pH and actual bicarbonate, within the
first 72 h of treatment were considered for analysis.
Measurements of other serum electrolytes and total
serum protein were analyzed at baseline and after 12, 24,
48, and 72 h. Additional laboratory parameters were an-
alyzed at baseline and at the end of the observation
period.
Endpoints for safety evaluation were occurrence of
severe alkalosis or acidosis (pH ≥7.55 or ≤7.20, re-
spectively) and severe hyper- or hypocalcemia (iCa ≥1.5
or ≤0.9 mmol/L, respectively) of any cause. The endpoint
for efficacy was filter lifetime.
Statistics
Descriptive statistics are presented as mean ± standard
deviation (SD) for continuous variables. For categorical
variables, relative frequencies are shown if not stated
otherwise. Individual data for treatment prescription and
acid–base measurements were recorded as changes
occurring during the study period. Graphics and descrip-
tive summaries at specific time points are based on
the individual last observation carried forward imput-
ation method (prescription data) and cubic spline in-
terpolation estimates (iCa and acid–base measurements)
per patient. Filter survival analysis was based on individual
filter data. For overall filter survival, observations were
censored at the end of the observation period only; for
clotting-free survival, observations were censored when
the filter was stopped for any reason except clotting.
Comparison between liver groups was performed
using one-way analysis of variance, the Kruskal-Wallis
test, and Fisher’s exact test where appropriate. Spearman’s
rank correlation was used to assess relationships between
continuous variables. Reasoning for sample size determin-
ation was based on the detection chance of rare events.
The chosen sample size of 120 provides a 90 % probability
that events with a general risk of 2 % or more would be
detected, and within each liver group (n = 40) events
with an occurrence probability of 5.5 % would have a
90 % chance of being observed. All analyses were per-




A total of 133 patients were included, of whom 48 were
stratified into the normal liver function group, 43 into
the mild LF group, and 42 into the severe LF group.
The type of ICU admission, the major reason for ICU
admission, and the risk, injury, failure, loss of kidneyfunction, end-stage kidney disease (RIFLE) classes at ini-
tiation of RCA-CVVHD were similar, with the exception
of cardiac disorders, which were a more frequent reason
for ICU admission in the groups with normal liver func-
tion and mild LF (42 % and 44 % vs. 19 % in severe LF;
p = 0.02). Overall types of ICU admission were medical
(56 %), post–cardiac surgery (14 %), post–other surgery
(24 %), posttrauma (4 %), and other (2 %). Major causes
for ICU admission were respiratory failure (42 %), sepsis
(39 %), and circulatory failure (35 %). RIFLE classes were
13.5 % risk, 15.8 % injury, and 67.7 % failure. Three per-
cent had preexisting dialysis-dependent chronic renal
failure. The causes of liver dysfunction did not differ be-
tween the mild and severe LF groups (p = 0.16). The eti-
ologies of LF were 39 % ischemic, 27 % multiple organ
dysfunction syndrome (MODS), 10 % alcohol abuse, 6 %
viral hepatitis, and 18 % unknown or other.
The most common reason (stated as percentage of pa-
tients, with multiple reasons possible) for choosing RCA
was either risk (74 %) or presence (20 %) of bleeding. In
14 %, RCA was the standard anticoagulant. An add-
itional indication for citrate anticoagulation (8 %) was
heparin-induced thrombocytopenia type II. A total of
100 patients were treated with RCA-CVVHD de novo,
and 33 patients were switched to RCA from other RRT
modalities. The average duration of previous RRT ses-
sions was 4.1 ± 4.8 days.
The patients’ characteristics at baseline are given in
Table 1. Other laboratory parameters at baseline and at
study end are given in Table 2. Of note, at baseline, the
mean international normalized ratio (INR) did not differ
significantly in the LF function groups (normal liver
function 1.7 ± 1.0, mild LF 1.5 ± 0.3, severe LF 1.8 ± 0.7),
and bilirubin and INR did not show a relevant correl-
ation in the study population (Spearman’s ρ = 0.18).
Filter lifetime during RCA-CVVHD
In total, in the group of 133 patients, 181 filters were
used. Among all patients, only one filter was used in
69 %, two filters were used in 26 %, and three filters
were used in 5 %. In 31 patients, RCA-CVVHD was
stopped before 72 h due to recovery and/or transport to
another department (n = 22), death (n = 6), or metabolic
complications (increase of total calcium [n = 2], meta-
bolic acidosis [n = 1]). The median evaluated treatment
time per patient was 71.1 h.
Treatment parameters are presented in Table 3. The
observation period ended after 72 h. Hence, in cases
where the filter was changed within 72 h, the maximum
filter lifetime is available for only the first filter. The
estimated filter survival for all filters was 56 % at the
maximum treatment observation time point of 72 h.
The observed median filter lifetime of the first filter
without censoring for non-clotting events was 70.4 h.








Number of patients 48 43 42 133
Age (yr) 70 ± 11 56 ± 15 61 ± 15 <0.0001 63 ± 15
Male sex 67 % 70 % 79 % 0.46 71 %
Body weight (kg) 79.9 ± 17.8 83.9 ± 25.0 78.1 ± 20.9 0.46 80.7 ± 21
Height (cm) 170.6 ± 12.5 171.5 ± 10.4 174.2 ± 7.2 0.31 172.0 ± 10
Length of ICU stay at study start (days) 2 ± 2 4 ± 9 7 ± 9 0.004 4 ± 8
SOFA score 12 ± 3 15 ± 3 16 ± 3 <0.001 14 ± 3
Diuresis (ml/day) 1006 ± 1335 620 ± 787a 603 ± 774a 0.11 754 ± 1027
Mechanical ventilation 79 % 74 % 71 % 0.70 75 %
FiO2 (L/L) 0.44 ± 0.17 0.48 ± 0.22 0.46 ± 0.22 0.72 0.46 ± 0.2
MAP (mmHg) 73 ± 12 74 ± 13 76 ± 12 0.61 74 ± 12
Vasopressor support 75 % 86 % 79 % 0.42 80 %
FiO2 fraction of inspired oxygen, ICU intensive care unit, MAP mean arterial pressure, SOFA Sequential Organ Failure Assessment
For continuous variables, mean ± standard deviation is given
ap = 0.04 for normal liver function vs. mild and severe failure
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did not differ significantly (normal liver function 70.7 h,
mild LF >72 h, severe LF 69.7 h). Overall, only 4 (97.8 %)
of 181 filters had to be changed because of clotting before




Number of patients 48
Total bilirubin (mg/dl) 0.8 ± 0.4 1.1 ± 0.8
Aspartate aminotransferase (U/L) 193 ± 454 196 ± 414
Alanine aminotransferase (U/L) 154 ± 602 104 ± 161
Creatinine (mg/dl) 3.5 ± 1.5 1.4 ± 0.7
Urea (mg/dl) 123 ± 75 53 ± 24
Sodium (mmol/L) 141 ± 5 142 ± 4
Potassium (mmol/L) 4.7 ± 0.7 4.3 ± 0.5
Phosphorus (mmol/L) 1.8 ± 0.9 0.8 ± 0.3
Magnesium (mmol/L) 1.1 ± 0.4 0.9 ± 0.1
Hematocrit (%) 30 ± 4 31. ±4
Platelet count (count/nl) 195 ± 170 159 ± 164
INR 1.7 ± 1.0 1.4 ± 0.7
aPTT (s) 52 ± 20 46 ± 10
Serum protein (g/dl) 4.9 ± 1.1 5.2 ± 1.0
Serum albumin (g/dl) 2.2 ± 0.6 2.2 ± 0.6
Total calcium (mmol/L) 2.0 ± 0.3 2.1 ± 0.2
Ratio total/ionized Ca2+ 1.8 ± 0.1 1.9 ± 0.1
Postfilter iCa (mmol/L) 0.27 ± 0.05 0.28 ± 0.03
aPTT activated partial thromboplastin time, iCa ionized calcium, INR international no
Mean ± SDwere 45 % diagnostic or surgical procedure, 18 % renal
recovery or change of therapy, 8 % death, 5 % catheter
dysfunction, 15 % CRRT-related, and 9 % other. Among
the cases with CRRT-related reasons for discontinuation,





Start End Start End
43 42
3.6 ± 1.3 4.5 ± 3.2 18.4 ± 13.0 17.0 ± 11.2
716 ± 1864 636 ± 2021 391 ± 1206 391 ± 1336
344 ± 766 361 ± 961 210 ± 476 199 ± 505
2.7 ± 1.4 1.4 ± 0.6 2.3 ± 1.1 1.6 ± 1.9
102 ± 59 49 ± 25 135 ± 69 74 ± 40
140 ± 6 142 ± 4 140 ± 7 140 ± 4
4.6 ± 0.8 4.4 ± 0.6 4.5 ± 0.7 4.3 ± 0.6
1.7 ± 0.8 0.8 ± 0.4 1.5 ± 0.7 1.0 ± 0.5
1.0 ± 0.4 0.9 ± 0.2 1.0 ± 0.3 1.0 ± 0.2
29 ± 5 30 ± 6 28 ± 5 29 ± 4
109 ± 85 92 ± 87 103 ± 91 98 ± 85
1.5 ± 0.3 1.4 ± 0.4 1.8 ± 0.7 1.7 ± 0.6
50 ± 12 49 ± 17 59 ± 25 54 ± 16
4.8 ± 1.1 5.0 ± 1.0 5.2 ± 1.1 5.3 ± 1.2
2.1 ± 0.6 2.3 ± 0.9 2.3 ± 0.6 2.3 ± 0.6
2.0 ± 0.4 2.3 ± 0.3 2.1 ± 0.3 2.3 ± 0.3
1.8 ± 0.1 1.9 ± 0.2 1.8 ± 0.2 2.0 ± 0.3
0.27 ± 0.06 0.29 ± 0.03 0.30 ± 0.03 0.30 ± 0.02
rmalized ratio







Start End Start End Start End
Blood flow (ml/min) 109 ± 24 114 ± 25 109 ± 25 117 ± 28 110 ± 24 107 ± 20
Dialysate flow (ml/h) 2144 ± 502 2292 ± 500 2128 ± 405 2328 ± 567 2098 ± 403 2319 ± 501
Net ultrafiltration (ml/h) 77 ± 108 74 ± 114 68 ± 100 84 ± 105 84 ± 103 85 ± 102
Citrate dose (mmol/L blood) 4.0 ± 0.1 3.8 ± 0.2 4.0 ± 0.1 3.9 ± 0.3 4.0 ± 0.1 4.1 ± 0.4
RCA-CVVHD regional citrate anticoagulation and continuous venovenous hemodialysis
Mean ± SD. For dialysate to blood flow ratio and calcium dose, see Figs. 2 and 3, respectively
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clotting before 72 h. One additional clotting incident oc-
curred at exactly 72 h. Three treatments were stopped be-
cause of metabolic complications (for details, see below).
Filter clotting occurred once in the normal liver function
group, thrice in the mild LF group, and once in the severe
LF group.
Episodes of severe acidosis during RCA-CVVHD
A total of 23 new episodes of severe acidosis (pH ≤7.20)
of any cause were observed in 19 patients. In seven
patients, severe acidosis was present at the initiation of
RCA-CVVHD. The minimum arterial pH in all patients
with at least one episode of severe acidosis ranged from
6.64 to 7.20, with a median of 7.17. The median time
until occurrence or detection of new severe acidosis was
3.9 h (range 0–57.2 h).
Three patients died during the study period without
resolving acidosis. These patients were already in critical
condition at baseline, with pH ranging from 7.08 to 7.28.Fig. 1 Survival probability of filters of regional citrate anticoagulation and c
line: all filter discontinuations. Dashed line: Clotting only (i.e., censored for nOne of these patients also developed severe hypocalce-
mia and is described in detail below (patients with signs
of citrate accumulation). Another patient with severe
lactic acidosis (pH = 7.0, base excess [BE] = −16.4, lac-
tate = 9.15 mmol/L) was switched after 16 h of RCA-
CVVHD to continuous venovenous hemodiafiltration
without anticoagulation. All other patients recovered
from severe acidosis during RCA-CVVHD within a me-
dian of 2 h (range 0.5–25 h).
The frequency distribution of episodes of severe acid-
osis was not different between the liver function groups
(normal liver function 13 %, mild LF 16 %, severe LF
14 %; p = 0.95).
Episodes of severe alkalosis during RCA-CVVHD
Three patients (normal liver function, one patient; mild
LF, none; severe LF, two patients; p = 0.41) developed
four episodes of severe alkalosis (maximum pH 7.56–
7.58). No patient had preexisting alkalosis. The time
until occurrence of alkalosis ranged from 8.8 to 47.2 hontinuous venovenous hemodialysis (RCA-CVVHD) circuits. Continuous
on-clotting events)
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after adjustment (increase) of the dialysate to blood flow
ratio within 3.0–6.0 h (median 6 h).
Acid–base status during RCA-CVVHD
Mean pH and bicarbonate concentration increased grad-
ually during the RCA-CVVHD treatment in all three
groups (Table 4, Fig. 2). There was no significant differ-
ence in blood pH, bicarbonate, or the blood flow to di-
alysate flow ratio between the liver function groups
(Figs. 2 and 3). The distribution of serum bicarbonate
concentrations was not different between groups at
study start (p = 0.67). The percentages of patients with
serum bicarbonate concentration <20 mmol/L were
32 % in the normal liver function group, 44 % in the
mild LF group, and 33 % in the severe LF group. Among
those patients, the frequency of patients reaching
bicarbonate concentrations within normal range (20–
26 mmol/L) during treatment and the time until serum
bicarbonate concentration reached normal range were
similar in all groups (normal liver function 93 %, mild LF
94 %, severe LF 79 %; p = 0.42; and normal liver function
13.2 h, mild LF 11.4 h, severe LF 11.8 h; p = 0.85). The fre-
quency of serum bicarbonate concentrations >26 mmol/L
was comparable (normal liver function 11 %, mild LF
15 %, severe LF 14 %). Of those patients, the frequency of
patients reaching bicarbonate concentrations within nor-
mal range during treatment and the time until serum
bicarbonate concentration reached normal range were
similar in all groups (normal liver function 100 %, mild LF
83 %, severe LF 100 %; p = 1.0; and normal liver function
17.8 h, mild LF 8.2 h, severe LF 8.0 h; p = 0.65).
Episodes of severe hypocalcemia during RCA-CVVHD
A total of 15 episodes of severe hypocalcemia (systemic
iCa ≤0.9 mmol/L) were observed in 15 patients (median
0.79, range 0.60–0.90 mmol/L). Three patients had pre-
existing severe hypocalcemia at the beginning of RCA-
CVVHD. In five patients, hypocalcemia was detected




Arterial pH 7.33 ± 0.10 7.41 ± 0.06
Arterial serum bicarbonate (mmol/L) 20.9 ± 4.8 25.2 ± 2.4
Base excess (mmol/L) −4.1 ± 5.8 1.3 ± 3.2
Arterial lactate (mmol/L) 2.27 ± 3.61 1.71 ± 2.22
Arterial pO2 (mmHg) 101 ± 34 96 ± 29
Arterial pCO2 (mmHg) 40 ± 11 41 ± 9
pCO2 carbon dioxide pressure, pO2 oxygen pressure, RCA-CVVHD regional citrate an
Mean ± standard deviation(time 0). In these patients, iCa measurements before the
treatment were not available. Therefore, the exact time of
onset of hypocalcemia could not be determined, but hy-
pocalcemia was most likely preexistent. In patients with
detection or onset of severe hypocalcemia after initiation
of RCA-CVVHD, the median time until occurrence was
0.5 h (range 0.0–44.0 h). One patient died during the
study period without the state of hypocalcemia resolving.
This patient is discussed in detail below. In the other
patients, severe hypocalcemia resolved after a median of
18.0 h (range 2.0–36.2 h). In the three patients with pre-
existing severe hypocalcemia, the time to resolution was
1.4 to 4.9 h. The number of patients with episodes of
hypocalcemia according to liver function groups was
normal liver function 8 %, mild LF 14 %, and severe LF
12 % (p = 0.70).
Episodes of severe hypercalcemia during RCA-CVVHD
No new severe hypercalcemia (iCa ≥1.5 mmol/L) was
observed during RCA-CVVHD. Three patients had pre-
existing severe hypercalcemia. All of these cases re-
solved, two within the first 30 minutes of RCA-CVVHD
treatment.
Systemic iCa and calcium dose during RCA-CVVHD by
group
As shown in Fig. 4, calcium dose and systemic iCa values
did not differ between the study groups (p = 0.42 for cal-
cium dose and p = 0.85 for iCa).
Bleeding episodes
Three patients (2 %) bled at the initiation of RCA-
CVVHD, and another five developed bleeding during
RCA-CVVHD (4 %).
Citrate dose during RCA-CVVHD
The mean ± SD citrate dose at the start of the study was
4.0 ± 0.1 mmol/L in each study group, and doses were
not different after 70 h of RCA-CVVHD (normal liver





Start End Start End
7.33 ± 0.10 7.44 ± 0.05 7.35 ± 0.10 7.42 ± 0.05
20.5 ± 5.2 25.8 ± 2.0 20.8 ± 4.3 24.7 ± 2.7
−4.6 ± 6.3 1.4 ± 6.8 −3.9 ± 5.0 −0.9 ± 6.8
3.78 ± 4.53 2.63 ± 3.25 2.81 ± 2.69 3.41 ± 4.93
99 ± 31 92 ± 28 93 ± 27 96 ± 21
41 ± 11 43 ± 8 39 ± 11 39 ± 7
ticoagulation and continuous venovenous hemodialysis
Fig. 2 Estimated mean ± standard deviation of arterial pH and serum bicarbonate concentrations during regional citrate anticoagulation and
continuous venovenous hemodialysis according to liver groups
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INR and the difference between citrate dose at the start of
the study and after 70 h (Spearman’s ρ = 0.03), indicating
that there was no detectable intention or need to reduce
the citrate dose in patients with higher INRs.
Patients with signs of citrate accumulation
Overall, three patients showed signs of citrate accumula-
tion [11]. In three patients, the ratio of systemic totalFig. 3 Estimated mean ± standard deviation of blood flow to dialysate flow
hemodialysis according to liver groupscalcium to iCa increased ≥2.5, and one of them also had
increased total calcium (≥2.8 mmol/L).
The first of these patients was admitted to the ICU
with fulminant acute LF and MODS (bilirubin 16.1 mg/
dl, INR 2.0) related to graft-versus-host disease after
stem cell transplantation. Lactic acidosis (pH = 7.28, oxygen
pressure = 66 mmHg, carbon dioxide pressure = 45 mmHg,
BE = −5.3 mmol/L, lactate = 3.55 mmol/L) was present at
the start of RCA-CVVHD. The patient died as a result ofduring regional citrate anticoagulation and continuous venovenous
Fig. 4 Estimated mean ± standard deviation of systemic arterial ionized calcium (iCa) and calcium dose during regional citrate anticoagulation
and continuous venovenous hemodialysis according to group
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BE = −23.4, lactate = 23.3 mmol/L) after 47 h of treat-
ment. This patient’s last systemic iCa measurement was
0.90 mmol/L and last total calcium level was 2.31 mmol/L.
Thus, the ratio of total calcium to iCa was not severely in-
creased (i.e., 2.57).
The second patient was admitted with severe sepsis and
MODS after partial liver resection (bilirubin 18.8 mg/dl,
INR 1.2). Serum chemistry at the start of the RCA-
CVVHD showed hyperlactatemia (2.5 mmol/L) and nor-
mal calcium status. A slight decrease of iCa was observed
after 15 minutes of RCA-CVVHD treatment, and iCa
decreased continuously, reaching a nadir of 0.85 mmol/L
after 12 h (total calcium 2.76 mmol/L, total calcium/iCa
ratio 3.24). Calcium substitution was increased in stepwise
fashion to 2.7 mmol/L, and the citrate dose was likewise
decreased to 2.5 mmol/L. After the next 15 h, both iCa
and total calcium totally returned into the normal range,
and the corresponding ratio was 2.07.
The third patient was admitted to the ICU with ful-
minant acute LF due to acetaminophen intoxication
(bilirubin 11.6 mg/dl, INR 4.8). The first iCa level, mea-
sured 40 minutes after initiation of RCA-CVVHD, was
0.9 mmol/L, and the calcium dose was increased from
1.7 to 2.0 mmol/L. After 6 h, this patient’s iCa level
decreased further to 0.62 mmol/L (i.e., severe hypocalce-
mia was present). The calcium dose was further increased
to 3.0 mmol/L, and the citrate dose was decreased to
3.0 mmol/L. Thereafter, the patient’s iCa concentration
gradually increased and reached normal range after 16 h.With these treatment settings, iCa remained stable but
total calcium concentration increased to 3.72 mmol/L
(total calcium/iCa ratio 3.23), indicating citrate accumula-
tion [2]. There were no significant changes in the pa-
tient’s acid–base parameters, and the patient’s INR
was 1.9 at this time point. Nevertheless, ongoing cit-
rate accumulation was suspected, and RCA-CVVHD was
stopped after 41 h.
Discussion
To our knowledge, this is the first multicenter pro-
spective study on the efficacy and safety of a citrate-
based CVVHD protocol in patients with liver dys-
function. The major results are, first, that RCA can
be applied safely and effectively in patients with se-
verely impaired liver function and, second, that in
these patients filter running times with RCA are
extraordinarily long. A great number of patients with
different degrees of LF in medical and surgical ICUs
were recruited. This allowed us to conduct compre-
hensive analyses based on a heterogeneous study popula-
tion, and the database is sufficiently large to support the
conclusions.
In the present study, filter clotting was a very rare
event. The filter lifetime censored for non-clotting treat-
ment interruptions even improved compared with the
first results published some years ago [6], using the same
protocol for RCA-CVVHD. In that early publication, fil-
ter survival with censoring for non-clotting events was
63 % at 72 h. In the present study, it was 98 %. This
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ments of RCA, such as the integration of citrate and cal-
cium pumps into the CRRT device and partial
automation of dose adaptations for citrate and calcium.
However, the present study shows, for the first time to
our knowledge, that with this protocol liver dysfunction
has no effect on the incidence of filter clotting. In
addition, experience in the use of RCA has increased.
Most important, there were no differences in the abil-
ity to metabolize citrate in critically ill patients with liver
dysfunction compared with those with normal liver
function. There was no increased risk for acidosis and
no need to lower the dialysate to blood flow ratio to
counteract metabolic acidosis as one would expect in
cases of insufficient metabolism of citrate to bicarbonate
(Fig. 3). This finding is in line with a prospective obser-
vational study in patients with severe LF treated with
RCA-CVVHD [15]. In another observational study, pa-
tients treated with an extracorporeal liver support sys-
tem also tolerated RCA [16]. Of note, in the present
study, acidosis resolved in 129 of 133 patients within the
72-h observation period. Persistent acidosis is a well-
known indicator of high mortality; in the present
study, three of the patients with persistent acidosis
died. The incidence of severe alkalosis was also inde-
pendent of liver dysfunction. Alkalosis per se was
mild, and its overall incidence was even lower than
reported for standard bicarbonate-buffered modalities
of CRRT with systemic anticoagulation [7, 17]. With
the use of an algorithm-guided adaption (increase) of
the dialysate to blood flow ratio, all alkalosis episodes
resolved within at most 6 h, showing again that
RCA-CVVHD allows rapid correction of metabolic al-
kalosis [10].
Seven patients developed severe hypocalcemia during
the study period. Again, the incidence was independent
of liver dysfunction. Because the number of patients and
especially the number of events were small, the observed
difference was not statistically significant, and there is a
probability of a type II error. No increase in the need for
calcium supplementation was observed in patients with
liver dysfunction, as could have been expected in cases
of impaired citrate metabolism and thus lack of release
of iCa from calcium-citrate complexes. Surprisingly, the
incidence and severity of hypocalcemia is similar to that
in other studies on the incidence of hypocalcemia in
critically ill patients without renal replacement therapy
[18, 19]. No new episodes of severe hypercalcemia oc-
curred during RCA-CVVHD treatment. Preexisting hy-
percalcemia was treated with RCA-CVVHD because it
allows control of arterial iCa in both directions by adapt-
ing calcium supplementation [20].
Signs of citrate accumulation were observed in three
patients. In one patient, the citrate accumulation wasonly mild and transient. The second patient had con-
comitant severe lactic acidosis. The most severe citrate
accumulation was found in the third patient, who had
acetaminophen intoxication. Citrate is metabolized via
the citric acid cycle, and its metabolism is oxygen-
dependent [21–23]. A state of intracellular hypoxemia or
an otherwise inhibited cellular respiration leads to im-
paired citrate metabolism. Hyperlactatemia and lactic
acidosis are signs of an anaerobic metabolic state. This
finding is in line with a retrospective analysis in patients
treated with RCA-CVVHD, showing that severe lactic
acidosis is strongly associated with impaired citrate me-
tabolism [24]. Interestingly, the mechanism of action in
acetaminophen intoxication is inhibition of mitochon-
drial respiration [25, 26]. We hypothesize that it is not
the state of liver function per se but a sufficient cellular
respiration that is essential for metabolism of citrate.
Median lactate concentrations were low and did not dif-
fer significantly between the liver function groups. This
is the most likely reason why we did not find a differ-
ence in the ability to metabolize citrate between the
groups. Liver dysfunction alone is not the major cause of
citrate accumulation.
In the present study, citrate dose was not different in
patients with LF. The relationship of coagulatory activity
and blood iCa concentration is not linear; that is, the
thromboelastography is totally unaffected with iCa con-
centrations >0.56 mmol/L [27, 28]. As shown before, for
an effective anticoagulation of the extracorporeal circuit,
a target range of 0.25–0.35 mmol/L for iCa is re-
quired. In cases of normal arterial iCa, a dose of ap-
proximately 4 mmol of citrate per liter of blood is
required to lower iCa into this target range. The present
study shows that these recommendations are appropriate
in patients with LF.
An apparent limitation of this study is the choice of
serum bilirubin as a parameter for liver function. Be-
cause no physiologic variable available for clinical use
allows early detection of hepatic dysfunction, current
diagnostic criteria are based on laboratory tests, mostly
serum bilirubin. Unlike other diagnostic criteria, serum
bilirubin remains a stable and powerful marker of hepatic
dysfunction, with elevated levels reflecting impairment in
the energy-consuming processes of heme metabolism,
conjugation, and bile secretion (for review, see [29]). One
may argue that a parameter of liver synthesis and func-
tion—namely, INR and Model for End-Stage Liver Disease
(MELD) score—may better correlate with the ability of
the liver to metabolize citrate. However, INR increases
often do not occur early in LF and represent only severe
forms of LF. Furthermore, INR is also increased in pa-
tients with disseminated intravascular coagulation fre-
quently observed in severe sepsis, and it is influenced
by substitution of plasma products. The MELD score
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ease and not for acute hepatic dysfunction, which was
the presentation of the majority of the patients in our
study population.
Serum bilirubin is a key component of prognostic
models in patients with acute LF [30]. Hence, we decided
to use bilirubin for classification of liver function in the
present study. This view is shared by others. Meier-
Kriesche et al. [11] used bilirubin for classification of liver
dysfunction in a study of RCA for CVVHD. They defined
LF as serum bilirubin >7 mg/dl. Even though citrate load
in their protocol was comparable to ours (9.3 g/h vs.
approximately 11 g/h), they reported a much higher inci-
dence of citrate accumulation as we observed in our
present study, using the same definition as we did—na-
mely, an increase in the total calcium to iCa ratio ≥2.5.
The mortality of the patients with citrate accumulation in
their study was very high, as 17 of 19 patients died during
the hospital stay. One can assume that the unfavorable
outcome of severely ill patients with LF and citrate accu-
mulation in the study of Meier-Kriesche et al. is in line
with impaired cellular respiration, as it was found to be
the major cause of disturbed citrate metabolism in the
present study. Furthermore, the 12 % incidence of citrate
accumulation in the total cohort treated with RCA was ra-
ther high compared with other studies on RCA, with inci-
dences of 0–1.24 % [3, 4, 6, 7], and with the present study
(2.3 %). In the present study, the majority of patients
showed LF secondary to ischemia or multiple organ failure
and not to primary liver disease as could be expected in a
mixed ICU patient population. On the basis of our data, a
higher incidence of citrate accumulation in patients with
LF due to primary liver disease cannot be excluded. An-
other issue might be seen in the limitation of the observa-
tion period to 72 h of treatment. According to the citrate
metabolism kinetics, the increase in the systemic citrate
concentration responsible for citrate accumulation can be
expected to occur quickly in the first hours of treatment,
whereas afterward a slower increase, or even a plateau
phase, should be achieved [31]. In that regard, if the
patient is at risk of accumulation of citrate, this accu-
mulation should be noticeable shortly after treatment
start. A 72-h observation period seems to be reasonable
because the patients in the liver dysfunction groups were
at risk for citrate accumulation from the beginning of
treatment.
Conclusions
The investigated protocol for RCA-CVVHD can be used
safely in patients with liver dysfunction. Furthermore, it
yields excellent filter patency and thus can be recom-
mended as first-line anticoagulation in almost all ICU
patients. Caution must be taken in patients with impaired
cellular respiration.Key messages
 This citrate anticoagulation protocol for CVVHD
can be used safely in patients with LF.
 It yields excellent filter patency and thus can be
recommended as first-line anticoagulation.
 Citrate accumulation in patients with LF is rare, but
caution is needed, particularly in patients with
impaired cellular respiration.
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